Literature DB >> 19710703

Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis.

H Tanaka, M Takeuchi, Y Takeda, S Sakai, D Abe, C Ohwada, E Sakaida, N Shimizu, Y Saito, S Miyagi, A Iwama, C Nakaseko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19710703     DOI： 10.1038/leu.2009.167

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors:  Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

2.  Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.

Authors:  Yusuke Takeda; Chiaki Nakaseko; Hiroaki Tanaka; Masahiro Takeuchi; Makiko Yui; Atsunori Saraya; Satoru Miyagi; Changshan Wang; Satomi Tanaka; Chikako Ohwada; Emiko Sakaida; Naoto Yamaguchi; Koutaro Yokote; Lothar Hennighausen; Atsushi Iwama
Journal:  Br J Haematol       Date:  2011-04-15       Impact factor: 6.998

3.  Somatically acquired mutations in primary myelofibrosis: A case report and meta-analysis.

Authors:  Yongming Xia; Qingxiao Hong; Zhibin Gao; Shijun Wang; Shiwei Duan
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

4.  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.

Authors:  Cedric Dos Santos; Tinisha McDonald; Yin Wei Ho; Hongjun Liu; Allen Lin; Stephen J Forman; Ya-Huei Kuo; Ravi Bhatia
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

5.  Functions of the Lyn tyrosine kinase in health and disease.

Authors:  Evan Ingley
Journal:  Cell Commun Signal       Date:  2012-07-17       Impact factor: 5.712

6.  Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.

Authors:  Y Nakaya; K Shide; T Niwa; J Homan; S Sugahara; T Horio; K Kuramoto; T Kotera; H Shibayama; K Hori; H Naito; K Shimoda
Journal:  Blood Cancer J       Date:  2011-07-22       Impact factor: 11.037

7.  Expression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice.

Authors:  Michelle T Graham; Clare L Abram; Yongmei Hu; Clifford A Lowell
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

8.  Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.

Authors:  N Telford; S Alexander; O J McGinn; M Williams; K M Wood; A Bloor; V Saha
Journal:  Blood Cancer J       Date:  2016-04-08       Impact factor: 11.037

9.  Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion.

Authors:  Hai-Ping Dai; Jia Yin; Zheng Li; Chun-Xiao Yang; Tin Cao; Ping Chen; Yun-Hui Zong; Ming-Qing Zhu; Xia-Ming Zhu; Sheng Xiao; De-Pei Wu; Xiao-Wen Tang
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.